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Gold nanoparticles as a substrate in bio-analytical
near-infrared surface-enhanced Raman
spectroscopy†
Holly J. Butler,a Simon W. Fogarty,a,b Jemma G. Kerns,c Pierre L. Martin-Hirsch,a
Nigel J. Fullwood*b and Francis L. Martin*a
As biospectroscopy techniques continue to be developed for screening or diagnosis within a point-of-
care setting, an important development for this ﬁeld will be high-throughput optimization. For many of
these techniques, it is therefore necessary to adapt and develop parameters to generate a robust yet
simple approach delivering high-quality spectra from biological samples. Speciﬁcally, this is important for
surface-enhanced Raman spectroscopy (SERS) wherein there are multiple variables that can be optimised
to achieve an enhancement of the Raman signal from a sample. One hypothesis is that “large” diameter
(>100 nm) gold nanoparticles provide a greater enhancement at near-infrared (NIR) and infrared (IR)
wavelengths than those <100 nm in diameter. Herein, we examine this notion using examples in which
SERS spectra were acquired from MCF-7 breast cancer cells incubated with 150 nm gold nanoparticles. It
was found that 150 nm gold nanoparticles are an excellent material for NIR/IR SERS. Larger gold nanopar-
ticles may better satisfy the theoretical restraints for SERS enhancement at NIR/IR wavelengths compared
to smaller nanoparticles. Also, larger nanoparticles or their aggregates are more readily observed via optical
microscopy (and especially electron microscopy) compared to smaller ones. This allows rapid and straight-
forward identiﬁcation of target areas containing a high concentration of nanoparticles and facilitating SERS
spectral acquisition. To some extent, these observations appear to extend to bioﬂuids such as blood plasma
or (especially) serum; SERS spectra of such biological samples often exhibit a low signal-to-noise ratio in
the absence of nanoparticles. With protein-rich bioﬂuids such as serum, a dramatic SERS eﬀect can be
observed; although this might facilitate improved spectral biomarker identiﬁcation in the future, it may not
always improve classiﬁcation between control vs. cancer. Thus, use of “large” gold nanoparticles are a good
starting point in order to derive informative NIR/IR SERS analysis of biological samples.
Introduction
Biospectroscopy techniques are gaining more widespread
usage in the bio-analytical field due to their ability to interro-
gate samples across a wide range of biomolecules, providing
detailed and specific (sub-)cellular information. The specific
vibrational nature of chemical bonds facilitates the acquisition
of spectra in the “biochemical fingerprint” region. Near-infra-
red (NIR) and infrared (IR) spectroscopies are beneficial for
bioanalysis as biological molecules absorb radiation in these
regions, unlike many non-biological samples.
Raman spectroscopy is a technique which has been
employed extensively in the analysis of a variety of diﬀerent
biological samples,1 including diﬀerent tissue types,2 individ-
ual cells,3 isolated cell components4 and biofluids.5 A key
advantage of Raman over other IR spectroscopy techniques,
such as Fourier-transform IR (FTIR), is the lack of inter-
ference from water. An absence of water interference is particu-
larly advantageous for live-cell studies6 and for use in vivo.1
Raman spectroscopy measures inelastic scattering caused
by energy transfer between incident excitation photons
and chemical bonds in a sample, which result in a change
in the vibrational mode of the chemical bond and the
energy, and thus the wavelength, of the scattered photon.
This shift in wavelength is specific to particular molecular
bonds, and readily interpreted from the output Raman
spectrum.
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However, there are significant limitations in the current
usage of Raman scattering for biological purposes. It is much
weaker than other scattering techniques, such as Rayleigh scat-
tering or fluorescence, and thus biological samples which are
typically weak Raman scatterers, may not give rise to an infor-
mation-rich spectrum. The influence of fluorescence on Raman
spectra is also problematic and can confound the biochemical
signature; this influence can be reduced by using lasers at IR
wavelengths. Additionally, cellular material is typically quite
fragile and thus samples can be easily damaged by higher laser
energies, introducing spectral artefacts into obtained data.
In order to overcome the limitations of conventional
Raman scattering, it is possible to use surface-enhanced
Raman spectroscopy (SERS). This is a phenomenon whereby
the Raman signal of a target sample is greatly enhanced when
placed into close proximity to a metal nanostructure.7,8 The
nanoscale roughness necessary for SERS is present in many
diﬀerent types of metal nanostructures, including roughened
electrodes, metal films and nanoparticles. In recent years, with
the wide-scale production of metal nanoparticles, more novel
forms of nanostructures have been identified as capable of
generating a SERS eﬀect. Nanostructure design for SERS experi-
ments is important as the enhancement varies. The level of
enhancement has been shown to reach up to 1014 times allow-
ing the potential of SERS in single molecule detection.9–12
Nanoparticles potentially have a myriad of uses for SERS
being able to specifically label sub-cellular regions both on the
cell surface and within the intracellular environment.13 The
dimensions of nanoparticles allow high localization of the
SERS enhancement eﬀect, permitting interrogation of a
sample at the specific sub-cellular regions labelled.14 However,
the degree of enhancement is dependent upon the physical
parameters of the nanoparticles used and how they interact
with the chosen excitation wavelength. Therefore, not all nano-
particle types will facilitate a large enhancement eﬀect from
the NIR or IR excitation wavelengths commonly used in bio-
analysis. This means that optimization of the nanoparticle
structure is required to gain suﬃcient enhancement from
samples at these specific wavelengths. There are many influen-
tial factors including size, shape and composition that need to
be considered for optimization of nanoparticle structure for
diﬀerent experimental Raman parameters;15,16 these have
been elegantly represented previously.17,18
Optimal experimental parameters are dependent upon the
sample, such as tissue type, individual cells or isolated cell
components, e.g., nuclei. Additionally, a particular analytical
target, such as a specific protein target, may require specific
labelling of metal nanoparticles to the target location, such as
antibody binding.19 However, there are many samples with
unknown targets for which the above labelling parameters are
not relevant, e.g., biofluids such as blood samples. Non-
specific labelling of metal nanoparticles has been demon-
strated using cationic gold labeling.20 Therefore, it is possible
to use nanoparticles without any type of targeting molecules
and to rely upon spontaneous associations of nanoparticles to
biomolecules within/on the sample.
Many studies have used gold and silver nanoparticles that
are 10 to 100 nm in diameter for SERS; however, theoretically
these small gold and silver nanoparticles may not be optimal
for use for NIR/IR SERS as their resonance wavelengths are
within the visible or ultraviolet regions.21 It is important to
consider that diﬀerent metals have distinct responses under
NIR/IR excitation. Gold and silver are good nanoparticle
materials because they are unreactive and stable in solution
compared to other metal nanoparticle types. Furthermore,
they are easy to acquire, either commercially or through chemi-
cal preparation.22,23 There is a need to expand on SERS theory
in order to find optimized metal nanostructures as SERS sub-
strates for these excitation wavelengths. It is important to note
that small nanoparticles have been shown experimentally to
provide surface enhancement at IR wavelengths.24
An increase in the diameter of gold or silver nanostructures
leads to a red shift in the resonance excitation wavelength,
therefore moving the resonance wavelength towards the NIR/IR
region.21 By increasing the size of the nanoparticles beyond
the electrostatic approximation (typically a diameter >100 nm),
more parameters become relevant, changing how the nanopar-
ticle reacts with the incident excitation light.25–27 This has led
to the theory that increasing the diameter of the metal nano-
particles used may be preferential for biological NIR SERS,
thus increasing its potential as a novel diagnostic tool.
Routine point-of-care bioanalysis requires a simple but
robust sample preparation procedure. In this study, we
examine whether SERS using 150 nm vs. 40 nm gold nanopar-
ticles could be applied robustly yet simply for bioanalysis. To
this end, we examine if large gold nanoparticles (150 nm in
diameter) give a strong SERS signal from MCF-7 cell samples.
Secondly, we investigate the potential of non-specific labelling
of nanoparticles (not attached to any targeting ligands) for the
development of a strong SERS signal in samples without
known or relevant targets for labelling, e.g., biofluids. Such a




Gold nanoparticles [150 (designated “large”) and 40 nm (desig-
nated “small”)] were obtained from British Biocell Inter-
national (UK) at a stock concentration containing 2.9 × 10−4
moles of gold per litre.
MCF-7 cell analysis
MCF-7 cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Lonza) with added foetal bovine serum
(FBS) (Lonza) and penicillin/streptomycin mixture (10%). Cells
were seeded in T25 flasks and cultured at 37 °C in 5% CO2 for
24 h. Once confluent, cells were disaggregated from each flask
using trypsinisation. They were then fixed with 70% ethanol
and 400 µl cell aliquots were placed on MIRR IR Low-E slides
(Kevley Technologies, USA) and allowed to air-dry overnight.
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Nanoparticle solution (400 µl of 150 nm) was then applied to
the dried cells and slides were again left to air-dry, before
being placed in a desiccator (Fig. 1A).
Raman spectra were acquired using an InVia Raman micro-
scope (Renishaw plc, Gloucestershire, UK) equipped with a
100 mW 785 nm excitation laser, which was calibrated to
520.5 cm−1 using a silicon calibration source. Spectral maps of
MCF-7 cells were acquired in a step-wise manner from the
target area at 1 µm step sizes (Fig. 2). Spectra were acquired at
0.1% laser power at 50× magnification for 1 second and 1
accumulation. Analysis of an MCF-7 cell clump was acquired
using StreamLine™ Raman analysis (Fig. 3) with an InVia
Raman microscope equipped with a 150 mW 785 nm exci-
tation laser, an exposure time of 10 seconds and 1 accumu-
lation. Laser powers of 0.05% (0.075 mW) and 0.1% (0.15 mW)
at source were used.
Post-SERS analysis, slides on which cells were deposited
were processed for scanning electron microscopy (SEM)
(Fig. 4). This involved mounting the slides onto aluminium
stubs and gold-coating in a 150A Edwards sputter coater
before examination at 15 KV in a JEOL 5600 digital scanning
electron microscope.
Fig. 2 Fixed MCF-7 cells on MIRR IR Low-E glass slides with 150 nm
gold nanoparticles subsequently added. A light micrograph image in (A)
shows labelling of MCF-7 cell with 150 nm nanoparticles (dark regions),
which co-localize with areas of high Raman signal intensity in (B) (red
areas). Scale bar = 10 µm.
Fig. 1 Schematic detailing the NIR SERS of sample preparations; (A) cellular sample; and, (B) bioﬂuid sample.
Fig. 3 The presence of large nanoparticles allows analysis of large
target areas rapidly using StreamLine™ Raman. A large cell clump seen
by light microscopy (A) was analysed to quickly give false colour image
maps; (B + D) = intensity at 1295 cm−1 (CH2 deformations); and, (C + E)
= signal to baseline at 1194–1228 cm−1 (Amide III).35 Areas of high inten-
sity (red) appear to correspond to areas of high nanoparticle localisation.
Also, by increasing laser power, regions of relevant high SERS expression
become easier to determine (B + C = 0.05% laser power; D + E = 0.1%
laser power). Scale bar = 20 µm.
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Blood plasma and serum analysis
Samples were obtained from the Genitourinary Tissue Biobank
at Lancashire Teaching Hospitals NHS Foundation Trust
(Preston, UK) with ethical approval [Research and Ethics Com-
mittee (REC) approval no.: 10/H0308/75]. From age-matched
cohorts of patients (n = 5 endometrial cancer, n = 5 non-cancer
control), plasma and serum samples were taken from storage
at −80 °C and thawed in a water bath at 37 °C for approxi-
mately 1 h. In order to compare the enhancement eﬀect of
nanoparticles at two distinct sizes, 200 µl aliquots of blood
plasma or serum were mixed with 200 µl of stock 150 nm or
40 nm gold nanoparticle solution (Fig. 1B). The resultant
mixture (total volume 400 µl) was applied to MIRR IR Low-E
slides and left to air-dry. Control slides without nanoparticles
were also prepared using 200 µl of blood plasma or serum
sample and allowed to air-dry. Blood SERS spectra were taken
at 10% laser power (2.4 mW at sample) at 50× magnification
across the 500–2000 cm−1 spectral range for 10 seconds and 1
accumulation; a minimum of 25 spectra per sample slide were
acquired. These air-dried samples could be examined under
optical brightfield microscopy to demonstrate the presence or
absence of nanoparticles (Fig. 5A). For transmission electron
microscopy (TEM), gold nanoparticles (40 or 150 nm) were
mixed 50 : 50 with blood serum and then 10 μl were pipetted
onto carbon-/formvar-coated electron microscope grids (Agar
Scientific, UK), blotted and allowed to dry before examination
with a 10-10 JEOL TEM.
Computational analysis was performed using MATLAB
(Mathworks, Natick, USA) with an in-house developed toolkit
(https://code.google.com/p/irootlab/), unless stated otherwise.28
The resultant Raman spectra were cut to 450–1700 cm−1 wave-
Fig. 4 Scanning electron micrographs of the gold nanoparticles on the
surface of the MCF-7 cells. (A) Shows an aggregated clump of 40 nm
nanoparticles (red arrows); (B) shows an aggregated clump of 40 nm
nanoparticles (red arrow) with a single 40 nm nanoparticle adjacent to it
(green arrow); (C) shows a single 150 nm nanoparticle on the cell
surface (green arrow); and, (D) shows at least two aggregated clumps of
nanoparticles (red arrows) as well as a single isolated 150 nm nanoparti-
cle (green arrow).
Fig. 5 Inﬂuence of nanoparticles on SERS eﬀect in blood plasma or serum samples. (A) Optical brightﬁeld microscopy images of blood plasma
samples with or without large (150 nm) gold nanoparticles. (B) Raman spectra (class means) of blood plasma (A, C, E) or serum samples (B, D, F) with
or without gold nanoparticles following polynomial baseline correction to show raw enhancement (A, B), polynomial baseline correction followed
by vector normalisation (C, D) and 1st order diﬀerentiation followed by vector normalisation (E, F).
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numbers inclusive of spectral peaks present in the sample and
wavelet de-noised. In order to display raw spectral enhance-
ment, spectra were polynomial baseline corrected maintaining
Raman intensity units (counts) (Fig. 5B-A, and B-B). For compu-
tational analysis, spectra were pre-processed using 1st order
diﬀerentiation followed by vector normalisation. Cross-validated
principal component analysis (PCA) with optimised principal
components (PC) factors followed by linear discriminant analy-
sis (LDA) was conducted in order to discriminate between
cancer vs. non-cancer patients (Fig. 6). Graphs were generated
in GraphPad Prism 4.0 software (GraphPad Software Inc, CA,
USA) and one-way analysis of variance (ANOVA) with Bonferroni
post-hoc tests was conducted to determine P-values for separ-
ation between cancer vs. non-cancer (Table 1).
Results and discussion
The potential for 150 nm gold nanoparticles to generate good
SERS enhancement is demonstrated; these larger nanoparti-
cles allow for ready visualisation using optical microscopy
(Fig. 2A). Fig. 2 shows an isolated MCF-7 cell labelled with
150 nm nanoparticles, which clearly demonstrates that regions
of high Raman signal co-localize with the presence of the
nanoparticles. Also, in Fig. 2B the signal appears to be highly
localized to the regions surrounding the nanoparticles rather
than being spread across the whole of the cell surface, support-
ing theoretical explanations of the SERS eﬀect. As the cells
were fixed prior to nanoparticles being added, one would
expect that they would be adhered to the outer cell surface
rather than having penetrated into the intracellular environ-
ment; therefore, the enhancement will be predominantly from
the cell membrane nearest the nanoparticles. Post-SERS analy-
sis using SEM (Fig. 4) shows that this is clearly the case. The
nanoparticles adhere to the surface either as single entities or
in aggregates. Compared to the smaller (40 nm) nanoparticles
(Fig. 4A and B), the larger (150 nm) nanoparticles are much
more readily detectable.
In Fig. 3, the application of rapid Raman scanning is tested
on similar MCF-7 cell samples to those analysed in Fig. 2. Here,
due to the capability of the StreamLine™ system to rapidly scan
across a sample, a large clump of cells with 150 nm nanoparticle
coverage was chosen for analysis. In the light microscope image
of the sample (Fig. 3A), aggregates of nanoparticles this time
appear as white spots across the cell surfaces. In false-colour
image maps (Fig. 3B and D), areas of high nanoparticle
expression show enhancement of the Raman signal. Also, Fig. 3C
and E show that the enhancement is not just an increase in
background signal but that relevant biological Raman signatures
are present, calculated from the high signal-to-baseline intensity.
These images show that, even despite the limiting factors of very
rapid acquisition time and low laser power, enhanced biological
spectra can be generated from large samples quickly using
“large” nanoparticles. This allows for the potential of rapid SERS
analysis of large tissue sections for diagnostics. Tissue sections
parallel to conventional H&E staining may be mapped using
SERS to facilitate high-throughput diagnosis.
The target area was analysed at two diﬀerent laser powers,
0.05% (0.075 mW) and 0.1% (0.15 mW) in order to assess the
sample with diﬀerent laser exposures. It is more desirable to
Fig. 6 Classiﬁcation of control vs. cancer Raman spectra following principal component analysis-linear discriminant analysis (PCA-LDA). Following
1st order diﬀerentiation followed by vector normalisation, each spectrum is reduced to a single point in a PCA-LDA scores plot. For each class, the
horizontal line represents the class mean.
Table 1 Classiﬁcation (control vs. cancer) of blood plasma or serum
samples with or without SERSa
Class comparison P-value Significant
Plasma
Control vs. cancer <0.001 Yes
Control vs. cancer (40 nm) <0.001 Yes
Control vs. cancer (150 nm) >0.05 No
Serum
Control vs. cancer >0.05 No
Control vs. cancer (40 nm) <0.001 Yes
Control vs. cancer (150 nm) >0.05 No
a Following acquisition of Raman spectra, one-way analysis of variance
(ANOVA) with Bonferroni post-hoc tests were conducted on class means
per sample to determine P-values for separation between cancer vs.
non-cancer.
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have very low laser powers to demonstrate the eﬀectiveness of
the SERS enhancement process. Previous studies have used
similar laser powers to generate large signal enhancements
from SERS samples.19,20 As the laser power is increased, it
appears that areas of SERS expression became more
evident with greater spatial resolution, and can still be
clearly defined from those without SERS enhancement. Another
advantage of large nanoparticles is that they can be observed
optically (Fig. 2A, 3A and 5A), where they appear as black or
white dots. The ability to see small aggregates of nanoparticles
or individual nanoparticles allows areas where they are abun-
dant to be manually targeted for analysis. This leads to highly-
enhanced spectra being acquired more easily from a sample.
Fig. 5B shows the analysis of blood plasma or serum
samples with or without SERS in order to investigate its poten-
tial to diﬀerentiate between control vs. endometrial cancer
samples. The search for blood-based cancer biomarkers is a
very important area for bioanalysis and a novel use for biospec-
troscopy. Previous studies have investigated the possibility of
biospectroscopy as a blood-based diagnostic tool.29–31
Fig. 5B-A and B-B show that either 40 nm or 150 nm nanoparti-
cles generate a SERS eﬀect, with the larger nanoparticles
giving rise to the more pronounced enhancement in the
protein-rich serum biofluid. Marked variation in the level of
SERS eﬀect even in the biofluids tested was noted (see ESI
Fig. S1–S3†). As one would expect, when these spectra are nor-
malised the SERS eﬀect is less apparent (Fig. 5B-C and B-D);
however, surprisingly many of the main peak intensities are
higher in control compared to cancer. The ready observation
of a SERS eﬀect in such biofluids lends promise towards deriv-
ing and identifying novel spectrochemical biomarkers.
However, the immediate objective of biospectroscopy is likely
to be towards classification and diagnosis/screening of
disease. To facilitate this, the Raman spectra were pre-
processed using 1st order diﬀerentiation followed by vector
normalization prior to classification using PCA-LDA. Interest-
ingly here, the use of smaller nanoparticles appears to give the
best classification in both blood plasma and serum whereas
the application of larger nanoparticles resulted in no between-
class significance (Fig. 6). One explanation could be that aggre-
gation of nanoparticles, even smaller ones, in a biofluid may
be suﬃcient to give rise to an optimal SERS eﬀect. Following
TEM of 150 nm nanoparticles post-mixing with serum, it is
noted that they form clusters, dimers and singlets (Fig. 7A). In
this instance, the 150 nm nanoparticles in the clusters are in
contact with each other and there is some variation in their
shape; one is clearly pentagonal rather than spherical. In the
case of 40 nm nanoparticles after mixing with serum, it is also
observed that they form clusters with what are probably
protein clumps (Fig. 7C). There are instances of the nanoparti-
cles being in small groups of two to four, which are in contact.
After mixing with serum, TEM shows 150 nm nanoparticles
associated with what are probably serum proteins (Fig. 7B).
Likewise, TEM shows 40 nm nanoparticles after mixing with
serum; again, they appear to be associated with what are prob-
ably proteins (Fig. 7D).
An important point to make for the use of nanoparticles for
larger studies, such as those for diagnostic development of
NIR-SERS, is that the preparation process can be made incred-
ibly rapid. Coupled with the rapid acquisition of SERS spectra, it
is possible to quickly analyse multiple samples to potentially
high sensitivity rates. The preparation is simple, allowing it to be
utilized without specialized expertise. Whilst nanoparticles are
suitable substrates, they do have some limitations for biological
NIR-SERS. They are not very amenable to live-cell imaging due to
the diﬃculty of cells to endocytose large nanoparticles through
simple incubation.32 Approaches such as electroporation may
facilitate this but this may lead to artefacts aﬀecting any resul-
tant spectra, distorting their reflection of underlying cellular
biochemical structure. Through investigating diﬀering nano-
structures,33,34 other sensitive NIR or IR SERS nanostructures
can be elucidated for use in bioanalytical research.35 Gold nano-
particles appear to be an optimal substrate for use in NIR or IR
SERS. Ready enhancement of Raman spectra coupled with the
rapid sample preparation and analysis increase the utility of
large nanoparticles for biological NIR-SERS. This methodology
greatly enhances the applicability of SERS as a high-throughput
technology for disease diagnosis.
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